EP 0988034 A1 20000329 - COX-2 SELECTIVE CARPROFEN FOR TREATING PAIN AND INFLAMMATION IN DOGS
Title (en)
COX-2 SELECTIVE CARPROFEN FOR TREATING PAIN AND INFLAMMATION IN DOGS
Title (de)
COX-2 SELEKTIVES CARPROFEN ZUR BEHANDLUNG VON SCHMERZ UND ENTZUENDUNG BEI HUNDEN
Title (fr)
CARPROFENE INHIBANT SELECTIVEMENT COX-2 ET UTILISE DANS LE TRAITEMENT DE LA DOULEUR ET DES INFLAMMATIONS CHEZ LES CHIENS
Publication
Application
Priority
- IB 9800662 W 19980501
- US 4563597 P 19970505
Abstract (en)
[origin: WO9850033A1] Treating or preventing inflammatory processes and diseases in dogs associated with the activity of inducible cyclo-oxygenase-2 (COX-2), while at the same time reducing or eliminating undesirable side effects associated with simultaneous inhibition of the activity of constitutive cyclo-oxygenase-1 (COX-1) by selectively inhibiting COX-2 activity with reference to COX-1 activity, wherein the selectivity ratio or COX-2 : COX-1 activity inhibition is at least 3 : 1 based on ex vivo inhibition levels measured in whole blood; the inhibitor is a member selected from the group of anti-inflammatory compounds consisting essentially of salicylic acid derivatives, p-aminophenol derivatives, indole and indene acetic acids, heteroaryl acetic acids, arylpropionic acids, anthranilic acids, enolic acids, and alkanones; the inhibitor in particular is comprised of (+)(S)-enantiomer of 6-chloro- alpha -methyl-9H-carbazole-2-acetic acid.
IPC 1-7
IPC 8 full level
A61K 31/403 (2006.01); A61K 31/40 (2006.01); A61P 29/00 (2006.01); A61P 43/00 (2006.01); C07D 209/88 (2006.01)
CPC (source: EP KR)
A61K 31/40 (2013.01 - EP KR); A61P 29/00 (2017.12 - EP); A61P 43/00 (2017.12 - EP)
Citation (search report)
See references of WO 9850033A1
Designated contracting state (EPC)
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU NL PT SE
DOCDB simple family (publication)
WO 9850033 A1 19981112; AP 9801234 A0 19991104; AR 011726 A1 20000830; AR 039628 A2 20050302; AU 6932198 A 19981127; BG 103852 A 20000630; BR 9808720 A 20000711; CA 2288759 A1 19981112; CN 1255059 A 20000531; DZ 2479 A1 20030201; EA 003696 B1 20030828; EA 199900895 A1 20000626; EP 0988034 A1 20000329; GT 199800063 A 19991026; HR P980244 A2 19990228; HU P0001286 A2 20001128; HU P0001286 A3 20001228; ID 21311 A 19990520; IL 132570 A0 20010319; IS 5220 A 19991019; JP 2000513020 A 20001003; KR 20010012300 A 20010215; KR 20040004406 A 20040113; MA 26491 A1 20041220; NO 995389 D0 19991104; NO 995389 L 20000104; NZ 500183 A 20020426; OA 11213 A 20030714; PA 8450601 A1 20000524; PE 72599 A1 19990812; PL 337003 A1 20000731; SK 148199 A3 20010911; TN SN98059 A1 20050315; TW 590773 B 20040611; UY 24989 A1 20011025; YU 55899 A 20030829; ZA 983722 B 19991104
DOCDB simple family (application)
IB 9800662 W 19980501; AP 9801234 A 19980504; AR P030101251 A 20030409; AR P980102089 A 19980505; AU 6932198 A 19980501; BG 10385299 A 19991103; BR 9808720 A 19980501; CA 2288759 A 19980501; CN 98804845 A 19980501; DZ 980089 A 19980302; EA 199900895 A 19980501; EP 98915041 A 19980501; GT 199800063 A 19980504; HR P980244 A 19980505; HU P0001286 A 19980501; ID 980651 A 19980501; IL 13257098 A 19980501; IS 5220 A 19991019; JP 54786998 A 19980501; KR 19997010252 A 19991105; KR 20037005258 A 20030414; MA 25059 A 19980504; NO 995389 A 19991104; NZ 50018398 A 19980501; OA 9900242 A 19991102; PA 8450601 A 19980505; PE 00033598 A 19980504; PL 33700398 A 19980501; SK 148199 A 19980501; TN SN98059 A 19980504; TW 87106689 A 19980430; UY 24989 A 19980504; YU 55899 A 19980501; ZA 983722 A 19980504